[1]
Kumdee, C., Yadee, J., Pantumongkol, W., Hadnorntun, P., Kittiratchakul, N., Leelahavarong, P., Suchonwanich, N. and Ekakkararungroj, C. 2021. Consequences and Enablers of the Selection of High-Cost Medicines to the National List of Essential Medicines Category E(2). Journal of Health Systems Research. 15, 4 (Dec. 2021), 456–476.